BIOVIE INC. (BIVI)
D
Pipeline Grade
Financial Position (from SEC Filings)
$13.1M
Cash & Equivalents
$14.9M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$17M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06847191 | NE3107 in Adults With Neurological Symptoms of Long COVID | PHASE2 | Active Not Recruiting | 203 |
| NCT06757010 | A Study of NE3107 in Early Parkinson's | PHASE2 | Active Not Recruiting | 60 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.